Get started
Author

Alvaro Jose Alencar

Observed names: A. Alencar, A. J. Alencar, Alvaro Alencar, Alvaro J Alencar, Alvaro J. Alencar
Observed institutions: Universitat Autònoma de Barcelona, Roswell Park Comprehensive Cancer Center, Northwell Health, Cleveland Clinic, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, University of Miami, Columbia University Irving Medical Center, Hospital de Sant Pau, Jackson Memorial Hospital, Bristol-Myers Squibb (United States), Rising Tide Foundation, University of Miami Health System, Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, Stanford Medicine, Sylvester Comprehensive Cancer Center, Institut de Recerca Sant Pau, Herbert Irving Comprehensive Cancer Center, The Ohio State University, University of Bologna, Stanford University
ORCID: 0000-0002-1720-9295
Observed ORCID: 0000-0002-1720-9295
OpenAlex ID: A5087628005
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
2021 · Anthony R Mato, Nirav N Shah, et al. · The Lancet · 467
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
2023 · Anthony R. Mato, Jennifer A. Woyach, et al. · New England Journal of Medicine · 234
Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment
2011 · Ash A. Alizadeh, Andrew J. Gentles, et al. · Blood · 200
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
2024 · Skye Montoya, Jessie Bourcier, et al. · Science · 168
PDF
MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP
2011 · Alvaro J. Alencar, Raquel Malumbres, et al. · Clinical Cancer Research · 142
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome
2004 · Daniel J. Lenihan, Alvaro J. Alencar, et al. · Blood · 122
PDF
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
2023 · Michael L. Wang, Wojciech Jurczak, et al. · Journal of Clinical Oncology · 121
PDF
CD25 Expression Is Correlated with Histological Grade and Response to Denileukin Diftitox in Cutaneous T-Cell Lymphoma
2006 · Rakhshandra Talpur, Daniel M. Jones, et al. · Journal of Investigative Dermatology · 106
Primary bone lymphoma – the University of Miami experience
2009 · Alvaro Alencar, David Pitcher, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 73
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial
2019 · Matthew S Davids, Danielle M Brander, et al. · The Lancet Haematology · 71
MiR-181 family-specific behavior in different cancers: a meta-analysis view
2018 · Cecilia Pop-Bica, Sebastian Pintea, et al. · Cancer and Metastasis Reviews · 62
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
2022 · Meletios A Dimopoulos, Paul G Richardson, et al. · The Lancet Haematology · 47
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
2024 · William G Wierda, Nirav N Shah, et al. · The Lancet Haematology · 40
Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation
2019 · Juan Pablo Alderuccio, Wei Zhao, et al. · American Journal of Hematology · 37
Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma
2007 · Izidore S. Lossos, Daniel Morgensztern, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 35
Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a/b Study
2024 · Nirav N. Shah, Zulfa Omer, et al. · Blood · 33
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
2024 · Michele D. Stanchina, Skye Montoya, et al. · Nature Reviews Clinical Oncology · 33
Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
2022 · William G. Wierda, David John Lewis, et al. · Blood · 31
Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study
2023 · Jennifer A. Woyach, Jennifer R. Brown, et al. · Blood · 28
LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study
2020 · Anthony R. Mato, John M. Pagel, et al. · Blood · 26
Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial
2024 · Juan Pablo Alderuccio, Alvaro J Alencar, et al. · The Lancet Haematology · 24
Autologous Stem Cell Transplantation in the Management of Relapsed Non-Hodgkin Lymphoma
2021 · Alvaro J. Alencar, Craig H. Moskowitz · Journal of Clinical Oncology · 20
Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
2022 · Michael L. Wang, Nirav N. Shah, et al. · Blood · 19
Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study
2023 · Jonathon B. Cohen, Nirav N. Shah, et al. · Blood · 18
Unusual Variants of Follicular Lymphoma
2019 · Jennifer R. Chapman, Jessica P. Alvarez, et al. · The American Journal of Surgical Pathology · 17
Works count: 153
Citation count: 2,493
H-index: 21
I10-index: 33
Year
Topic
Type